TE Connectivity Named Massachusetts Manufacturer of the Year

Massachusetts Manufacturing Caucus recognizes global leader in components for minimally invasive medical devices

TE Connectivity (TE), a global leader in connectors and sensors, has been named Manufacturer of the Year by the Massachusetts Legislature’s Manufacturing Caucus.

TE’s plant in Medway, Mass. produces precision engineered parts that are key to the manufacturing of medical devices including endoscopes, vascular access guide wires, venous introducers, catheters and many other minimally invasive devices. Approximately 125 people are employed at the 80,000-square-foot facility.

“TE Connectivity was one of 55 manufacturers and honorees from across the state who are truly ‘making it’ in Massachusetts, exemplifying how government and industry can work together to have a meaningful impact on society,” said State Rep. Jeffrey N. Roy (D-Franklin), who nominated TE Connectivity. “For more than 75 years, TE Connectivity has helped to solve tomorrow’s toughest challenges with advanced connectivity and sensor solutions. Their solutions power electric vehicles, aircraft, digital factories, and smart homes as well as enabling life-saving medical care, sustainable communities, efficient utility networks, and the global communications infrastructure. These represent great contributions to the Massachusetts economy and ecosystem, and I was delighted that we could honor TE Connectivity’s work.”

The Massachusetts Legislature’s Manufacturing Caucus includes a group of more than 60 legislators from around the commonwealth. Lawmakers focus on training for manufacturing employees, encouraging innovation by helping start-ups access resources and expanding apprenticeship in key manufacturing sectors. This is the seventh year for the award, which was presented to TE at the Massachusetts Manufacturing Mash-Up at Polar Park in Worcester.

“We are proud to be part of the Massachusetts MedTech community and look forward to continuing our work here to have a profound impact on the lives of patients and their loved ones globally,” said TE Quality Manager Sid Jayaraman, who accepted the award on behalf of TE.

TE’s roots in Massachusetts go back to the founding of Microgroup, Inc. in 1971 in Holliston. Microgroup moved to Medway in 1983 and was acquired by TE in 2017, making it a vital part of the company’s global medical business.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”